Solid Biosciences Inc. (SLDB)

Solid Biosciences Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	-	-	8.09	13.62	-
Revenue Growth (YoY)	-	-	-40.57%	-	-
Cost of Revenue	96.43	76.56	78.42	58.74	-
Gross Profit	-96.43	-76.56	-70.33	-45.12	-
Selling, General & Admin	33.3	27.75	24.08	27.14	21.58
Research & Development	-	-	-	-	64.88
Operating Expenses	33.3	27.75	24.08	27.14	86.46
Operating Income	-129.73	-104.32	-94.4	-72.25	-86.46
Interest Expense	-0.34	-0.44	-	-	-
Interest & Investment Income	9.47	7.58	2.62	0.06	0.12
Other Non Operating Income (Expenses)	-4.1	1.1	-0.38	0	0
EBT Excluding Unusual Items	-124.7	-96.08	-92.17	-72.19	-86.35
Merger & Restructuring Charges	-	0.06	-12.05	-	-1.94
Other Unusual Items	-	-	18.24	-	-
Pretax Income	-124.7	-96.02	-85.98	-72.19	-88.29
Earnings From Continuing Operations	-124.7	-96.02	-85.98	-72.19	-88.29
Net Income	-124.7	-96.02	-85.98	-72.19	-88.29
Net Income to Common	-124.7	-96.02	-85.98	-72.19	-88.29
Shares Outstanding (Basic)	41	20	9	7	3
Shares Outstanding (Diluted)	41	20	9	7	3
Shares Change (YoY)	105.27%	133.60%	19.59%	105.58%	28.91%
EPS (Basic)	-3.06	-4.83	-10.10	-10.14	-25.50
EPS (Diluted)	-3.06	-4.83	-10.10	-10.14	-25.50
Free Cash Flow	-100.67	-95.7	-100.99	-79.05	-57.5
Free Cash Flow Per Share	-2.47	-4.81	-11.87	-11.11	-16.61
Operating Margin	-	-	-1166.35%	-530.50%	-
Profit Margin	-	-	-1062.28%	-530.01%	-
Free Cash Flow Margin	-	-	-1247.74%	-580.36%	-
EBITDA	-127.27	-101.73	-92	-69.29	-82.54
D&A For EBITDA	2.46	2.58	2.41	2.96	3.92
EBIT	-129.73	-104.32	-94.4	-72.25	-86.46

Updated Mar 6, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q